Loading…

Browse All Grants

20,252 grants found

Filters
Reset

Showing 2,9612,980 of 20,252 grants

Active NON-SBIR/STTR RPGS
Epigallocatechin gallate for prevention of lethal cirrhosis complications
NATIONAL CANCER INSTITUTE Ut Southwestern Medical Center United States 2023 – 2028

Summary Hepatocellular carcinoma (HCC) is the leading cause of death in patients with cirrhosis, and the fastest rising cancer mortality in the U.S. Due to the limited efficacy of...

$6.85M
USD
Active NON-SBIR/STTR RPGS
Neurotrophic strategy to mitigate chemotherapy-related brain injury
NATIONAL CANCER INSTITUTE University of California-Irvine United States 2023 – 2028

ABSTRACT Cancer-related cognitive impairment (CRCI), often referred as “chemobrain”, is prevalent up to 75% of all breast cancer survivors. These impairments cause significant dist...

$4.71M
USD
Active NON-SBIR/STTR RPGS
Feasibility of artesunate to improve HPV and cervical precancer treatment outcomes among HIV positive women in LMICs
NATIONAL CANCER INSTITUTE University of North Carolina Chapel Hill United States 2023 – 2026

ABSTRACT Women living in low- and middle-income countries (LMICs) face a disproportionate burden of incidence and mortality from cervical cancer, accounting for 85% of incident cas...

$2.47M
USD
Active NON-SBIR/STTR RPGS
Evaluation of Pre-Analytical Factors of Urine Samples for Urine Cancer Cell Cultures (UCCC) --A Non-Invasive Biomarker – in Monitoring Response and Recurrence of Bladder Cancer
NATIONAL CANCER INSTITUTE Ohio State University United States 2023 – 2028

PROJECT SUMMARY Bladder cancer is one of the top 10 most frequent cancers, yet the most underfunded cancer by NCI based on funding dollars and ratio of funding/mortality. There has...

$3.6M
USD
Completed SBIR-STTR RPGS
Methods for Fast and Efficient Oxygen Imaging
NATIONAL CANCER INSTITUTE O2M Technologies, Llc United States 2023 – 2025

Abstract Intermittent or acute/cyclic hypoxia in tumors, with frequencies between a few cycles per minute to hours, is receiving increased attention because this type of hypoxia ha...

$4M
USD
Completed NON-SBIR/STTR RPGS
Leveraging the Hidden Genome to Recover the Missing Heritability of Cancer
NATIONAL CANCER INSTITUTE Sloan-Kettering Inst Can Research United States 2023 – 2025

PROJECT SUMMARY Decades of research into the genetic epidemiology of cancer have led to much knowledge about the heritability of the disease. However, findings have largely focused...

$4.55M
USD
Active NON-SBIR/STTR RPGS
Promoting a Culture Of Innovation, Mentorship, Diversity and Opportunity in NCI Sponsored Clinical Research: NCI Research Specialist (Clinician Scientist) Award Application of Janice M. Mehnert, M.D.
NATIONAL CANCER INSTITUTE New York University School of Medicine United States 2023 – 2028

Janice M. Mehnert, M.D., is the Associate Director (AD) for Clinical Research, Director, Melanoma and Cutaneous Oncology and a tenured Professor of Medicine at the Perlmutter Cance...

$1.11M
USD
Completed SBIR-STTR RPGS
Time-lapse Flow Cytometry for Kinetic Profiling of T-Cell Function
NATIONAL CANCER INSTITUTE Lase Innovation Inc United States 2023 – 2025

Abstract Despite progress in immunotherapies, there are significant challenges to overcome to make them more broadly applicable to different cancers and more effective for patients...

$8.37M
USD
Active NON-SBIR/STTR RPGS
Comprehensive Analysis of Best Practices for Clinical Testing of Malignant Pleural Effusion Specimens
NATIONAL CANCER INSTITUTE University of California, San Francisco United States 2023 – 2028

PROJECT SUMMARY/ABSTRACT Patients with advanced cancers often develop malignant pleural effusions (MPEs), a collection of fluid that develops between the surface of the lung and th...

$3.51M
USD
Active NON-SBIR/STTR RPGS
Clinical Trials Specialist in Developmental Therapeutics
NATIONAL CANCER INSTITUTE Columbia University Health Sciences United States 2023 – 2028

Project Summary The planned activities describe a set of efforts that will build upon my interest in developmental therapeutics and childhood leukemias. I will lead a team of physi...

$1.76M
USD
Completed SBIR-STTR RPGS
Time-lapse Flow Cytometry for Kinetic Profiling of T-Cell Function
NATIONAL CANCER INSTITUTE Lase Innovation Inc United States 2023 – 2025

Abstract Despite progress in immunotherapies, there are significant challenges to overcome to make them more broadly applicable to different cancers and more effective for patients...

$10.02M
USD
Active NON-SBIR/STTR RPGS
Comprehensive Analysis of Best Practices for Clinical Testing of Malignant Pleural Effusion Specimens
NATIONAL CANCER INSTITUTE University of California, San Francisco United States 2023 – 2028

PROJECT SUMMARY/ABSTRACT Patients with advanced cancers often develop malignant pleural effusions (MPEs), a collection of fluid that develops between the surface of the lung and th...

$3.69M
USD
Active NON-SBIR/STTR RPGS
Develop Conditionally Armored CAR Macrophage Therapy for Pancreatic Cancer
NATIONAL CANCER INSTITUTE Rutgers Biomedical and Health Sciences United States 2023 – 2028

SUMMARY/ABSTRACT Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers with limited therapeutic options. About 95% PDAC patients harbor oncogenic mutant KRAS (KRA...

$6.03M
USD
Active NON-SBIR/STTR RPGS
Promoting a Culture Of Innovation, Mentorship, Diversity and Opportunity in NCI Sponsored Clinical Research: NCI Research Specialist (Clinician Scientist) Award Application of Janice M. Mehnert, M.D.
NATIONAL CANCER INSTITUTE New York University School of Medicine United States 2023 – 2028

Janice M. Mehnert, M.D., is the Associate Director (AD) for Clinical Research, Director, Melanoma and Cutaneous Oncology and a tenured Professor of Medicine at the Perlmutter Cance...

$1.11M
USD
Completed NON-SBIR/STTR RPGS
Defining therapeutic strategies for boosting T-cell infiltration into cold tumors with spatial proteomics and machine learning
NATIONAL CANCER INSTITUTE California Institute of Technology United States 2023 – 2025

Project Summary Immunotherapies such as immune checkpoint inhibitors and chimeric antigen receptor (CAR-T) cell therapy have been highly successful in reversing cancer progression...

$4.23M
USD
Active OTHER RESEARCH-RELATED
CAPRISA CASCADE Clinical Trials Network Clinical Research Site
NATIONAL CANCER INSTITUTE Centre/Aids Programme/Res/South Africa South Africa 2023 – 2027

Summary The Center for the AIDS Program of Research in South Africa (CAPRISA) CASCADE Clinical Trials Network Clinical Research Site, aims to provide clinical trial infrastructure...

$2.16M
USD
Active NON-SBIR/STTR RPGS
Clinical Trials Specialist in Developmental Therapeutics
NATIONAL CANCER INSTITUTE Columbia University Health Sciences United States 2023 – 2028

Project Summary The planned activities describe a set of efforts that will build upon my interest in developmental therapeutics and childhood leukemias. I will lead a team of physi...

$1.76M
USD
Active NON-SBIR/STTR RPGS
Develop Conditionally Armored CAR Macrophage Therapy for Pancreatic Cancer
NATIONAL CANCER INSTITUTE Rutgers Biomedical and Health Sciences United States 2023 – 2028

SUMMARY/ABSTRACT Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers with limited therapeutic options. About 95% PDAC patients harbor oncogenic mutant KRAS (KRA...

$5.73M
USD
Active OTHER RESEARCH-RELATED
CAPRISA CASCADE Clinical Trials Network Clinical Research Site
NATIONAL CANCER INSTITUTE Centre/Aids Programme/Res/South Africa South Africa 2023 – 2027

Summary The Center for the AIDS Program of Research in South Africa (CAPRISA) CASCADE Clinical Trials Network Clinical Research Site, aims to provide clinical trial infrastructure...

$3.41M
USD
Active NON-SBIR/STTR RPGS
NCI Clinical Trial Research Strategy, Harnessing of Equity, and Implementation
NATIONAL CANCER INSTITUTE University of California, San Diego United States 2023 – 2028

PROJECT SUMMARY/ABSTRACT I am a female board-certified radiation oncologist and Professor at the University of California (UC), San Diego, in the Department of Radiation Medicine....

$1.74M
USD